Myopic Degeneration

Myopic degeneration is a long-term eye condition that happens in people with high myopia (very nearsighted eyes). In high myopia, the eyeball grows too long from front to back. Because the eye is too long, images focus in front of the retina instead of on it, which causes blurry distance vision. Over the years, this extra length puts constant stretch on the back of the eye (the posterior pole). This repeated stretch slowly thins and weakens the deeper eye layers: the sclera? (white coat), the choroid (blood-vessel layer), and the retina (the seeing layer).

The main reason is excessive axial elongation, which means the eye keeps growing longer, especially in childhood and teenage years, and the outer coat of the eye (sclera) and the layers inside (choroid, Bruch’s membrane, and retina) get stretched and thinned. Over time this stretching can cause posterior staphyloma, which is a bulging of the back wall of the eye, and this bulge changes the normal shape of the retina and can lead to traction, splits, or atrophy in the macula, which is the center of sharp vision. These structural changes explain why someone with very high myopia may first see well with glasses and later lose vision even with the right prescription?. Expert consensus reviews explain these changes and emphasize that pathologic myopia is the myopia type that truly reduces best-corrected vision because of the tissue damage, not just because of refractive blur. PMCPubMed

Types

Doctors use simple categories that describe what the back of the eye looks like in photographs or scans, and these categories help track severity and risk.

1. Myopic maculopathy categories (META-PM / IMI)

• C0 – No maculopathy: The macula looks normal even though the eye is myopic.

• C1 – Tessellated fundus?: The retina looks like a mosaic because the underlying vessels show through a thinned layer; this is an early visible change.

• C2 – Diffuse atrophy: There is widespread thinning and paleness around the macula, and the choroid under the retina is thin.

• C3 – Patchy atrophy: There are well-defined pale patches where the retina and choroid have atrophied more deeply.

• C4 – Macular atrophy: The atrophy involves the center of the macula and usually causes significant central vision loss.

• “Plus” lesions: These are extra lesions that increase the risk of vision loss: lacquer cracks (tiny cracks in Bruch’s membrane), myopic macular neovascularization (abnormal new blood vessels under the macula), and Fuchs spots (pigmented scars after bleeding). These “plus” lesions can appear at any category and raise the risk of sudden or permanent vision loss. PubMedaes.amegroups.orgPMC

2. Other patterns seen in pathologic myopia

• Posterior staphyloma: A bulging of the back of the eye that changes the contour and increases stress on the macula.

• Myopic traction maculopathy: The retina is pulled and can split (schisis) or detach because of traction from the vitreous or from the curved back wall.

• Dome-shaped macula: A localized? inward bulge within a staphyloma, which can alter fluid movement and vision.

• Peripapillary changes and myopic optic neuropathy?: Tissue around the optic nerve? thins and may be associated with glaucoma-like damage in highly myopic eyes. These are well-described imaging patterns in recent retina reviews. Retina TodayPMC

Causes and contributors

Each item below explains something that can start, drive, or worsen the disease changes in the back of a highly myopic eye.

1. Eye grows too long (axial elongation): The longer the eye, the greater the stretch and the higher the risk of degeneration. PMC

2. Genetic? tendency: Some families carry many genes that make eyes grow longer and raise lifetime risk. PMC

3. Posterior staphyloma development: A bulging back wall focuses mechanical stress on the macula and speeds damage. Retina Today

4. Thinning of the choroid: The blood-rich layer under the retina becomes thin, so the retina receives less support. PMC

5. Breaks in Bruch’s membrane (lacquer cracks): Tiny cracks make bleeding and scarring more likely. Review of Ophthalmology

6. Abnormal new vessels under the macula (myopic CNV/MNV): Fragile vessels leak or bleed and can scar. AAO Journal

7. Vitreous traction on a curved posterior pole: Pulling forces can split the retina (schisis) or detach it. PMC

8. Less time outdoors in childhood: Low outdoor light exposure is linked to eye growth that is too fast and long. BioMed CentralMDPI

9. Heavy near work with little outdoor balance: Intense study with little outdoor time increases risk in many populations. BioMed Central

10. Early age of onset? of myopia: When myopia starts young, eyes have more years to elongate. PMC

11. Ethnic and geographic patterns: Some Asian populations show higher prevalence and faster progression?, reflecting genetics and environment together. PMC

12. High educational pressure and urban living: These correlate with less outdoor time and more near work, raising risk. BioMed Central

13. Connective-tissue disorders (e.g., Marfan, Stickler): These conditions weaken eye support tissues and favor elongation. PMC

14. Thinning and remodeling of the sclera: The outer coat of the eye loses strength and stretches more easily. PMC

15. Choroidal circulation impairment: Reduced blood supply under the retina supports atrophy and degeneration. Review of Ophthalmology

16. Age and cumulative wear: The longer the tissues stay stretched, the more likely atrophy and cracks appear. PMC

17. Parental myopia: Having one or both myopic parents increases risk for high myopia and later degeneration. PMC

18. Eye shape asymmetry and tilt: Tilted discs and uneven curvature concentrate stress in the macula. PMC

19. Prior macular hemorrhage or scar: Old bleeds and scars mark weak areas that can reopen or expand. Review of Ophthalmology

20. Overall polygenic risk combined with lifestyle: Many small genetic effects plus little outdoor time push eye growth beyond safe limits. PMC

Symptoms

1. Blurry distance vision that slowly worsens: Even with updated glasses, central clarity drops when macular damage appears. PMC

2. Distorted straight lines (metamorphopsia): Lines bend or wobble when the macula is pulled, swollen, or scarred. AAO Journal

3. A dark or gray spot in the center (central scotoma): Damage or bleeding under the macula blocks central vision. AAO Journal

4. Sudden blur after a small bleed: A tiny macular hemorrhage from a lacquer crack or new vessel can cause a quick change. Review of Ophthalmology

5. Reduced contrast: Letters fade into the background because macular cells and their support layers are thin. PMC

6. Color looks washed-out: Severe? macular atrophy can desaturate colors. PMC

7. Wavy or broken letters when reading: Traction or schisis affects fine detail. PMC

8. Difficulty seeing faces or small print: Central damage lowers the finest resolution. PMC

9. New floaters or brief flashes: Liquefying vitreous and lattice changes are common in very long eyes. PMC

10. Worse night vision quality: Thin choroid and atrophy reduce light capture and signal quality. PMC

11. Eye strain? and visual fatigue?: Working hard to overcome distortion leads to tired eyes. PMC

12. Paracentral blind spots: Patchy atrophy creates missing areas near the center. aes.amegroups.org

13. Micropsia (things look smaller): A stretched macula can “minify” images. PMC

14. Sensitivity to glare: Damaged macula and RPE handle bright light poorly. PMC

15. Slow recovery after bright light: Photoreceptors under stress recover more slowly. PMC

Diagnostic tests

Important note in simple language: Not every test below is used for every patient. Doctors pick the tests that match the symptoms, the eye exam, and the need to confirm or monitor certain complications. Guidelines and reviews emphasize exam, refraction, and imaging (especially OCT) as the core tests; other tests are used when needed. PMC

A) Physical examination

1. Pupil? examination for a relative afferent pupillary defect: The doctor shines a light to make sure the optic nerve and retina are sending balanced signals; this checks for significant asymmetry or nerve damage that can accompany very long eyes. PMC

2. Ocular alignment and motility check: The doctor watches how eyes move and line up, because very long eyes can have subtle alignment issues that affect comfort and reading. PMC

3. Slit-lamp examination of the front of the eye and vitreous: The doctor looks for lattice degeneration, floaters, posterior vitreous detachment, and lens changes, which are common in high myopia and may relate to traction at the back. PMC

4. Dilated fundus examination (indirect ophthalmoscopy): This is the key bedside exam to see tessellation, atrophy, lacquer cracks, staphyloma contours, and any fresh bleeding. aes.amegroups.org

B) Manual or psychophysical tests

5. Best-corrected visual acuity? (ETDRS or Snellen): This measures how much central detail the eye can resolve with the best prescription and is the baseline? for tracking change over time. PMC

6. Refraction (objective and subjective): Autorefraction and retinoscopy estimate lens power, and fine-tuning checks how much of the blur is optical versus retinal disease. PMC

7. Amsler grid: A simple square grid shown one eye at a time helps detect distortion or missing spots from macular traction, CNV, or atrophy. AAO Journal

8. Contrast sensitivity testing (e.g., Pelli-Robson): This looks at how well the eye sees faded letters and can show macular dysfunction even when high-contrast letters look okay. PMC

C) Lab and pathological tests ( tests—used selectively)

9. Targeted genetic testing for connective-tissue disorders (e.g., FBN1 for Marfan, COL2A1 for Stickler) when systemic? features are present: These tests help explain unusually high eye length and guide family counseling. PMC

10. Infectious and inflammatory serology? if the appearance is atypical? for myopic disease (e.g., syphilis or toxoplasma studies): This is done when the doctor suspects a “masquerade” that can mimic myopic scars or bleeding. PMC

11. Research-level or referral genetic risk assessment? for high myopia: Polygenic risk tools exist mainly in research and selected clinics and can flag people at higher lifetime risk. PMC

D) Electrodiagnostic tests ( tests—used when structure and function do not match)

12. Full-field electroretinogram (ERG): This measures the overall responses of rod and cone cells; it helps when vision is very poor but the scans do not fully explain it. PMC

13. Multifocal ERG: This maps macular function and can show areas of depressed responses in macular atrophy or traction. PMC

14. Visual evoked potentials (VEP): This measures the signal reaching the brain; it helps separate macular disease from optic-nerve problems in complex high-myopia cases. PMC

E) Imaging and biometric tests (tests—the backbone of diagnosis? and follow-up)

15. Optical coherence tomography (OCT): This is the key cross-sectional scan that shows macular atrophy, schisis, traction, tiny foveal detachments, or a dome-shaped macula; it guides almost every decision. Retina Today

16. OCT angiography? (OCT-A): This shows blood-flow maps without dye and can detect myopic macular neovascularization or confirm inactivity after treatment. Retina Today

17. Fluorescein angiography (FA): A dye test that highlights leakage from abnormal new vessels and helps plan anti-VEGF therapy when needed. AAO Journal

18. Color fundus photography (including ultra-widefield): High-resolution photos document tessellation, atrophy borders, lacquer cracks, and Fuchs spots and allow progression tracking. aes.amegroups.org

19. Axial length optical biometry (e.g., IOLMaster/Lenstar): This measures eye length precisely, which is a crucial risk marker and a way to monitor long-term change. PMC

20. B-scan ultrasound? (when media are cloudy or to map staphyloma shape): This helps when cataract, hemorrhage, or a very curved posterior wall hides the view. Retina Today

Non-Pharmacological Treatments (Therapies & Others)

These approaches do not involve taking medicine, but they protect vision, cut risk, or support daily life. I explain the goal (“Purpose”) and how it helps (“Mechanism”).

1. Accurate, full-time optical correction (glasses/contacts)
   Purpose: Sharpest possible vision; reduces eye strain.
   Mechanism: Places the focus on the retina so the brain gets the best image; does not reverse degeneration but improves function.

2. Myopia-control optics in children (orthokeratology, dual-focus/multifocal soft lenses)
   Purpose: Slow eye elongation during growth years.
   Mechanism: Alters peripheral focus to reduce the growth signal that lengthens the eye.

3. Outdoor time for kids (≥2 hours/day)
   Purpose: Lower risk of myopia onset and progression.
   Mechanism: Bright natural light influences retinal dopamine and growth pathways.

4. Ergonomic reading habits (30–40 cm distance, good lighting)
   Purpose: Reduce near-work stress.
   Mechanism: Less sustained focus demand lowers accommodative strain and may reduce progression pressure in youth.

5. 20-20-20 rule for screens
   Purpose: Reduce strain and dryness.
   Mechanism: Every 20 minutes, look 20 feet away for 20 seconds to relax focus and blink more.

6. Protective eyewear for sports and risky tasks
   Purpose: Prevent trauma? in a thinned, vulnerable eye.
   Mechanism: Shields against impact and foreign bodies.

7. UV-blocking sunglasses outdoors
   Purpose: Protect ocular tissues and comfort.
   Mechanism: Cuts UV and blue-violet exposure that contribute to oxidative stress.

8. Smoking cessation
   Purpose: Preserve circulation and reduce oxidative damage.
   Mechanism: Improves small-vessel health that supports the choroid/retina.

9. Blood pressure and metabolic control
   Purpose: Stabilize the micro-circulation that feeds the retina.
   Mechanism: Healthy vessels leak less and heal better when treated.

10. Sleep hygiene
    Purpose: Support overall ocular physiology and daily function.
    Mechanism: Regular sleep helps hormonal rhythms that affect eye comfort and repair.

11. Low-vision rehabilitation? (if central vision is reduced)
    Purpose: Maintain independence and reading ability.
    Mechanism: Training + tools (magnifiers, high-contrast settings, text-to-speech) maximize remaining vision.

12. Home safety and fall prevention
    Purpose: Avoid injuries when depth perception or contrast is reduced.
    Mechanism: Good lighting, high-contrast steps, and decluttered paths lower accident risk.

13. Amsler grid self-monitoring?
    Purpose: Catch CNV early.
    Mechanism: Daily/weekly check of straight lines helps detect new waviness or spots; prompt review saves vision.

14. Frequent scheduled eye exams (typically every 6–12 months, or sooner if high risk)
    Purpose: Find silent changes before vision drops.
    Mechanism: OCT/OCTA detect fluid or traction early; treatment works best when fast.

15. Peripheral retina prophylaxis (doctor-decided laser around weak spots)
    Purpose: Reduce detachment risk in selected cases.
    Mechanism: Strong “welding” bonds at tear edges to prevent spread.

16. Blink training and humidification for dry-eye symptoms
    Purpose: Comfort and sustained reading.
    Mechanism: Regular blinking and moist air reduce surface dryness that worsens blur.

17. Task lighting and high-contrast tools
    Purpose: Easier reading and safer movement.
    Mechanism: Brighter, directed light enlarges the effective print contrast.

18. Education on warning symptoms
    Purpose: Empower fast action in emergencies.
    Mechanism: Knowing signs of CNV or detachment leads to earlier care.

19. Balanced physical activity
    Purpose: Vascular and metabolic health.
    Mechanism: Exercise supports micro-circulation that nourishes the eye.

20. Myopia-control counseling for families
    Purpose: Long-term plan for kids of highly myopic parents.
    Mechanism: Combines outdoor time, optical options, and (if appropriate) atropine to slow axial growth.

Drug Treatments

Medication mainly helps myopic CNV (leaky new vessels) and childhood progression (atropine). Doses below are typical clinical? doses; actual regimens are tailored by your retina specialist or pediatric eye doctor.

1. Ranibizumab (anti-VEGF) — intravitreal injection
   Class: Anti-VEGF biologic.
   Dose/Timing: 0.5 mg (0.05 mL) injected into the eye; often a “1+PRN” plan for myopic CNV (one injection, then as needed based on OCT).
   Purpose: Stop leakage and bleeding under the macula.
   Mechanism: Blocks VEGF, a growth signal for abnormal vessels.
   Side effects: Eye discomfort, small floaters, rare infection (endophthalmitis), pressure rise; systemic risk is low but discussed.

2. Aflibercept (anti-VEGF) — intravitreal injection
   Class: Anti-VEGF fusion protein.
   Dose/Timing: 2 mg (0.05 mL) per injection; similar PRN approach for myopic CNV.
   Purpose/Mechanism: Same goal—dry up fluid, stop growth of CNV by trapping VEGF.
   Side effects: Similar to ranibizumab.

3. Bevacizumab (anti-VEGF, off-label) — intravitreal injection
   Class: Anti-VEGF monoclonal antibody.
   Dose/Timing: 1.25 mg (0.05 mL) per injection, PRN.
   Purpose: Cost-effective option widely used off-label for CNV.
   Mechanism/Side effects: Like others in its class; infection risk is low but serious.

4. Conbercept (anti-VEGF; availability varies by region)
   Class: Anti-VEGF fusion protein.
   Dose/Timing: Typical intravitreal dosing per local guidelines.
   Purpose: Treat myopic CNV where approved.
   Mechanism: VEGF blockade.
   Side effects: Similar anti-VEGF risks.

5. Brolucizumab (anti-VEGF; use for myopic CNV is limited/variable)
   Class: Anti-VEGF single-chain antibody fragment.
   Dose/Timing: Intravitreal per protocol; candidacy cautious due to inflammation risk.
   Purpose/Mechanism: Strong drying effect by VEGF inhibition.
   Side effects: Rare but serious intraocular inflammation and occlusive vasculitis have been reported; retina specialists weigh risk–benefit carefully.

6. Verteporfin Photodynamic Therapy (PDT)
   Class: Light-activated drug therapy.
   Dose/Timing: IV verteporfin, then laser of specific wavelength to the CNV area.
   Purpose: Seal abnormal vessels; used mainly before widespread anti-VEGF or when injections aren’t possible.
   Mechanism: Activated drug causes local vessel closure.
   Side effects: Light sensitivity for a few days; must avoid bright light to prevent skin reactions.

7. Atropine eye drops (low-dose) for progression control (children/teens)
   Class: Antimuscarinic.
   Dose/Timing: 0.01%–0.05% one drop in each eye nightly, typically during growth years.
   Purpose: Slow axial length growth, lowering future degeneration risk.
   Mechanism: Acts on retinal/scleral signaling that drives eye elongation.
   Side effects: Mild light sensitivity and near blur at higher doses; low-dose is better tolerated.

8. Pirenzepine gel (where available; less common now)
   Class: Selective antimuscarinic.
   Dose/Timing: Topical gel twice daily in studies.
   Purpose: Myopia control in children.
   Mechanism: Similar signaling modulation as atropine.
   Side effects: Local irritation; availability is limited.

9. Topical carbonic anhydrase inhibitors (e.g., dorzolamide) — selected cases
   Class: CAI eye drops.
   Dose/Timing: 2–3 times daily in short courses, if there is macular edema/schisis in selected scenarios.
   Purpose: Try to reduce certain fluid pockets; evidence is limited and case-based.
   Mechanism: Alters retinal fluid transport.
   Side effects: Burning, bitter taste; rare allergy.

10. Oral acetazolamide — selected short courses
    Class: Systemic CAI.
    Dose/Timing: Commonly 250 mg 1–2× daily for a few days when specifically indicated by a retina specialist.
    Purpose: Temporarily reduce retinal fluid in select situations; not routine.
    Mechanism: Fluid dynamics shift.
    Side effects: Tingling, taste changes, diuresis; avoid in sulfa allergy; interacts with other meds.

Important: Steroid eye drops are not standard for myopic CNV and can raise eye pressure. Any injection or drug choice should be made by a retina specialist after imaging.

Dietary “Molecular” Supplements (supportive; not cures)

Supplements don’t reverse structural stretching, but they support retinal metabolism and antioxidant defenses. Always discuss with your doctor—doses can interact with other conditions.

1. Lutein — 10 mg/day
   Function: Macular pigment support for contrast and glare.
   Mechanism: Filters blue light and acts as an antioxidant in photoreceptors.

2. Zeaxanthin — 2 mg/day
   Function/Mechanism: Partners with lutein in macular pigment; similar benefits.

3. Omega-3 (EPA+DHA) — ~1,000 mg/day combined
   Function: Anti-inflammatory lipid support for retina and tear film.
   Mechanism: Resolvin pathways improve cell membrane function.

4. Vitamin C — 500 mg/day
   Function: Antioxidant recycling (with vitamin E and glutathione).
   Mechanism: Neutralizes free radicals in oxidative stress.

5. Vitamin E — up to 200 IU/day
   Function: Protects cell membranes from oxidative damage.
   Mechanism: Lipid antioxidant; don’t exceed if you’re on anticoagulants without advice.

6. Zinc — ≤25–40 mg elemental/day (short-term unless supervised)
   Function: Cofactor for retinal enzymes.
   Mechanism: Supports antioxidant enzymes; high doses may cause copper deficiency, so balance is key.

7. Copper — 2 mg/day (only with higher zinc use)
   Function/Mechanism: Prevents copper deficiency anemia when taking zinc.

8. Astaxanthin — 6–12 mg/day
   Function: Potent antioxidant; may aid endurance of ciliary muscle and retinal resilience.
   Mechanism: Quenches singlet oxygen/free radicals.

9. Saffron extract (crocin/crocetin) — 20–30 mg/day
   Function: May improve retinal function metrics in some macular conditions.
   Mechanism: Antioxidant/neuroprotective effects.

10. Coenzyme Q10 — 100–200 mg/day
    Function: Mitochondrial energy support.
    Mechanism: Electron transport chain cofactor; supports high-energy retinal cells.

Note: Beta-carotene is avoided in smokers due to lung risk. Supplements are adjuncts, not replacements for medical/surgical treatment.

Immunity-Booster / Regenerative / Stem-Cell” Drugs (state of the science)

There are no approved “immune-booster” or stem-cell drugs that treat myopic degeneration today. Still, research is active. For transparency, here are six investigational approaches. Dosage: not established (clinical-trial only). Use: not approved; discussed only to explain where the field is going.

1. iPSC-derived RPE cell therapy
   Function: Replace damaged retinal pigment epithelium under the macula.
   Mechanism: Sheet or patch of lab-grown RPE supports photoreceptors; surgical implantation.

2. Retinal progenitor cell injections
   Function: Attempt to rescue or replace degenerating retinal cells.
   Mechanism: Paracrine neurotrophic support ± limited integration.

3. Mesenchymal stem cell (MSC)–derived exosomes
   Function: Deliver growth factors and microRNAs to reduce inflammation and support repair.
   Mechanism: Paracrine signaling; injected locally or systemically in trials.

4. Scleral reinforcement biomaterials (tissue engineering)
   Function: Thicken/strengthen posterior sclera to resist further elongation.
   Mechanism: Bio-scaffold to redistribute stress; overlaps with surgery.

5. Anti-fibrotic molecular therapies (e.g., TGF-β pathway modulators)
   Function: Reduce scarring after CNV.
   Mechanism: Targets pathways that drive fibrosis under the macula.

6. Gene-targeted modulation of scleral remodeling (MMP inhibitors, etc.)
   Function: Slow axial lengthening by altering collagen turnover.
   Mechanism: Adjusts the “remodeling” enzymes that thin the sclera.

Again: these are not standard care, and doses are not defined outside trials.

Surgeries

1. Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling
   Why: For myopic macular hole, retinoschisis, or traction causing central vision loss.
   What happens: The gel (vitreous) is removed; delicate ILM is peeled to relieve traction; gas may be used to help the hole close.

2. Macular buckle (posterior buckle)
   Why: For macular hole with detachment or severe posterior staphyloma with traction.
   What happens: A specially shaped buckle is placed on the outer wall of the eye behind the macula to support the stretched area.

3. Posterior scleral reinforcement (PSR)
   Why: To strengthen the back wall of very long eyes and potentially slow further elongation in select cases.
   What happens: A graft or strip is sutured onto the posterior sclera to mechanically support it. (Use varies by region/center.)

4. Retinal detachment repair (scleral buckle and/or vitrectomy)
   Why: To fix retinal tears or detachments, which are more likely in highly myopic eyes.
   What happens: Tears are sealed with laser/cryo; buckles indent the wall; vitrectomy removes traction; gas or oil may be placed.

5. Cataract surgery (with careful biometry)
   Why: Myopic eyes often develop earlier cataracts; removing a cloudy lens improves clarity.
   What happens: Cloudy lens removed, artificial lens implanted; measurements are tailored because long eyes need special formulas.

Practical Prevention Tips

1. For kids: daily outdoor time (≥2 hours) to reduce onset/progression.

2. Consider myopia-control optics (ortho-K or dual-focus lenses) during growth years.

3. Low-dose atropine in appropriate children under specialist care.

4. Healthy reading habits: good light, proper distance, regular breaks.

5. Don’t rub the eyes hard—thinned tissues are delicate.

6. Quit smoking and avoid secondhand smoke.

7. Control blood pressure, sugar, and cholesterol.

8. Wear sunglasses outdoors and protective eyewear for sports.

9. Keep regular retina check-ups (every 6–12 months, or sooner if advised).

10. Know red-flag symptoms (sudden distortion, new central blur, flashes/floaters, curtain) and act fast.

When to See a Doctor

• Immediately (same day or ER):
  – A sudden dark spot in the center of vision.
  – New wavy lines or rapid worsening distortion.
  – A curtain/shadow from the side, or many new floaters with flashes.

• Soon (within days):
  – Gradual central blur or distortion that’s new.
  – Small central gray spot that persists.
  – Bleeding noticed in the eye or sudden drop after strain.

• Routine (as scheduled):
  – High myopia with no symptoms: typically every 6–12 months, sooner if your eye doctor recommends based on imaging.

What to Eat & What to Limit

Eat more of:

1. Leafy greens (spinach, kale) for lutein/zeaxanthin.

2. Oily fish (salmon, sardines) 2–3×/week for omega-3s.

3. Colorful fruits/veg (orange/yellow/red) for antioxidants.

4. Nuts and seeds (walnuts, flax) for healthy fats and minerals.

5. Eggs (yolks contain carotenoids) if suitable for your diet.

Limit or avoid:

1. Smoking (biggest avoid).
2. Ultra-processed foods high in sugar/salt that harm vessels.
3. Excess alcohol, which adds oxidative stress.
4. Very high-dose unbalanced supplements without guidance (e.g., high zinc without copper).
5. Crash diets—the retina needs steady nutrients.

Frequently Asked Questions

1) Is myopic degeneration the same as just being very nearsighted?
No. High myopia is a strong glasses prescription. Myopic degeneration means the back of the eye has structural damage from long-term stretching.

2) Can glasses or contacts stop myopic degeneration?
They improve clarity but do not stop the structural changes. Monitoring is still essential.

3) Will I go blind?
Most people do not go blind, but some lose central detail from CNV or macular atrophy. Early treatment and regular imaging help protect vision.

4) How do anti-VEGF shots help?
They dry up leaky new vessels under the retina and can stabilize or improve central vision. Many patients need few injections for myopic CNV compared with other diseases.

5) Is photodynamic therapy (PDT) still used?
Anti-VEGF is first-line in most places. PDT is an alternative when injections aren’t possible or as a backup.

6) Can surgery fix the “long” eye?
We can treat complications (traction, detachment) and support the back wall (macular buckle/PSR in select cases), but we can’t shrink the eye back to normal.

7) Are blue-light-filter glasses necessary?
They reduce glare and eye strain for some people. There’s no solid proof they stop degeneration, but comfort can be helpful.

8) Do screens cause myopic degeneration?
Screens don’t directly cause degeneration. In children, lots of near work with little outdoor time increases myopia risk, which later raises degeneration risk.

9) Should I avoid exercise?
Normal exercise is good for vascular health. Avoid contact sports without eye protection and follow your surgeon’s instructions after any procedures.

10) Can diet cure myopic degeneration?
No. Diet supports eye health but does not reverse structural thinning. It’s an adjunct to medical care.

11) I have new wavy lines on an Amsler grid. What now?
That can signal fluid or bleeding under the macula. See a retina specialist promptly.

12) How often will I need injections?
Myopic CNV often needs fewer injections than age-related macular degeneration, but it varies. Your doctor bases it on OCT/OCTA findings.

13) Can kids outgrow high myopia?
No. Myopia typically stabilizes in late teens/20s. Control strategies in childhood can slow progression, lowering later risk.

14) Are “immune boosters” useful for this disease?
There’s no proven immune-booster drug for myopic degeneration. Focus on evidence-based care and healthy habits.

15) What’s the single most important thing I can do?
Know the warning signs and keep regular imaging-based follow-ups. Quick treatment of CNV or retinal tears saves vision.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 20, 2025.